Diabetes is associated with increased liver cancer incidence and mortality in adults: A report from Asia Cohort Consortium

Nhan Thi Ho,Sarah Krull Abe,Md. Shafiur Rahman,Rashedul Islam,Eiko Saito,Prakash C. Gupta,Mangesh S. Pednekar,Norie Sawada,Shoichiro Tsugane,Akiko Tamakoshi,Takashi Kimura,Xiao‐Ou Shu,Yu‐Tang Gao,Woon‐Puay Koh,Hui Cai,Wanqing Wen,Ritsu Sakata,Ichiro Tsuji,Reza Malekzadeh,Akram Pourshams,Seiki Kanemura,Jeongseon Kim,Yu Chen,Hidemi Ito,Isao Oze,Chisato Nagata,Keiko Wada,Yumi Sugawara,Sue K. Park,Aesun Shin,Jian‐Min Yuan,Renwei Wang,Sun‐Seog Kweon,Min‐Ho Shin,Hossein Poustchi,Hossein Molavi Vardanjani,Habibul Ahsan,Kee Seng Chia,Keitaro Matsuo,You‐Lin Qiao,Nathaniel Rothman,Wei Zheng,Manami Inoue,Daehee Kang,Paolo Boffetta
DOI: https://doi.org/10.1002/ijc.34965
2024-04-27
International Journal of Cancer
Abstract:What's New Diabetes, which is highly prevalent in Asian countries, has been associated with risk of liver cancer. Here, the authors present one of the largest population‐based studies examining the relationship between diabetes and liver cancer incidence and mortality. They analyzed data from 20 pooled cohort studies from multiple countries throughout Asia and found a statistically significant relationship between baseline diabetes and increased liver cancer incidence and mortality. The association, which varied by country, suggests that better diabetes prevention and management may contribute to prevention of liver cancer. There has been growing evidence suggesting that diabetes may be associated with increased liver cancer risk. However, studies conducted in Asian countries are limited. This project considered data of 968,738 adults pooled from 20 cohort studies of Asia Cohort Consortium to examine the association between baseline diabetes and liver cancer incidence and mortality. Cox proportional hazard model and competing risk approach was used for pooled data. Two‐stage meta‐analysis across studies was also done. There were 839,194 subjects with valid data regarding liver cancer incidence (5654 liver cancer cases [48.29/100,000 person‐years]), follow‐up time and baseline diabetes (44,781 with diabetes [5.3%]). There were 747,198 subjects with valid data regarding liver cancer mortality (5020 liver cancer deaths [44.03/100,000 person‐years]), follow‐up time and baseline diabetes (43,243 with diabetes [5.8%]). Hazard ratio (HR) (95% confidence interval [95%CI]) of liver cancer diagnosis in those with vs. without baseline diabetes was 1.97 (1.79, 2.16) (p
oncology
What problem does this paper attempt to address?